Back to Search

JENNIFER BYRD, R.PH, PHARM.D.

R.PH, PHARM.D.

Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist

NPI: 1407489784Individual

Specialties, Licenses & Credentials

Pharmacist Clinician (PhC)/ Clinical Pharmacy SpecialistPrimary

Pharmacist — Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist

Code: 1835P0018X

03325641(OH)

Research & Publications (20)

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
PMID 17003373·Blood·2007
3-trial
Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia.
PMID 17671129·Clin Cancer Res·2007
3-trial
Treatment of relapsed chronic lymphocytic leukemia: old and new therapies.
PMID 16616068·Semin Oncol·2006
6-review
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
PMID 16344317·J Clin Oncol·2006
8-other
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
PMID 15930354·Clin Cancer Res·2005
3-trial
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
PMID 15466934·Blood·2005
3-trial
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
PMID 15138165·Blood·2005
4-observational
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
PMID 15020610·J Clin Oncol·2004
3-trial
Chronic lymphocytic leukemia.
PMID 15561682·Hematology Am Soc Hematol Educ Program·2004
6-review
KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.
PMID 12595316·Blood·2003
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

Contact & Hours

Address
2100 MICHIGAN ST
SIDNEY, OH 45365

Quick Facts

NPI
1407489784
Entity Type
Individual
Gender
Female
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile